Telix Pharmaceuticals Limited (TLPPF)
| Market Cap | 5.63B |
| Revenue (ttm) | 430.80M |
| Net Income (ttm) | 32.82M |
| Shares Out | n/a |
| EPS (ttm) | 0.10 |
| PE Ratio | 171.58 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,598 |
| Average Volume | 3,680 |
| Open | 16.80 |
| Previous Close | 16.70 |
| Day's Range | 16.47 - 16.93 |
| 52-Week Range | 6.88 - 16.93 |
| Beta | 2.38 |
| RSI | 60.12 |
| Earnings Date | Feb 19, 2025 |
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatmen... [Read more]
News
Illuccix® Receives European Approval
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive dec...
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managin...
Telix Pharmaceuticals Ltd (TLX) Reports Strong Q4 2024 Performance and Strategic Advancements
Telix Pharmaceuticals Ltd (TLX) Reports Strong Q4 2024 Performance and Strategic Advancements
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operat...
Telix Pharmaceuticals Acquires ImaginAb's Next-Gen Therapeutic Pipeline
Telix Pharmaceuticals Acquires ImaginAb's Next-Gen Therapeutic Pipeline
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase...
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce...
Telix Pharmaceuticals Submits BLA for Kidney Cancer Imaging Agent
Telix Pharmaceuticals Submits BLA for Kidney Cancer Imaging Agent
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics L...
Telix Pharmaceuticals: Australian Company And A Solid Recent U.S. IPO
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
MELBOURNE, Australia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new asset...
Telix ADSs Commence Trading on Nasdaq
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced tr...
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
MELBOURNE, Australia and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and ...
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & ...
Telix Pharmaceuticals: Strong Momentum Presents Opportunity
Telix Pharmaceuticals leverages a novel theranostic approach, offering a unique risk-reward model in the challenging biotech climate. Find out why TLPPF stock is a Buy.
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
MELBOURNE, Australia, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle Me...
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
MELBOURNE, Australia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma1, which has the mission of expanding g...
Telix Files Form 20-F Registration Statement for Nasdaq ADS
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement (Registrati...
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
MELBOURNE, Australia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter...
Health Canada Approves Label Expansion for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Health Canada has approved the use of Illuccix® (kit for the p...
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
MELBOURNE, Australia and INDIANAPOLIS, Ind. and LAKE MARY, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharm...
Focus on supply chain and manufacturing in expansion plans: Telix Pharma CEO
Christian Behrenbruch, CEO of Telix Pharmaceuticals says the short shelf life of the company's key products means supply chains management is crucial for product distribution.
Telix Pharmaceuticals Limited (TLPPF) Q2 2024 Earnings Call Transcript
Telix Pharmaceuticals Limited (OTCPK:TLPPF) Q2 2024 Earnings Conference Call August 22, 2024 7:00 PM ETCompany ParticipantsKyahn Williamson - Senior Vice...
Focus on supply chain and manufacturing in expansion plans: Telix Pharma CEO
Christian Behrenbruch, CEO of Telix Pharmaceuticals says the short shelf life of the company's key products means supply chains management is crucial for product distribution.
Telix Pharmaceuticals Limited 2024 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Telix Pharmaceuticals Limited in conjunction with their 2024 Q2 earnings call.